Cellectis UCART Milestone: One step closer to a Universal CAR-T Therapy for Blood Cancer

29/10/2015 - 2 minutes

Cellectis is a leader in immuno-oncology CAR-T therapies from France, which might revolutionise cancer treatments. Now, the next step in the CAR-T campaign is to step away from personalised (autologous) therapies, which are time-consuming and expensive, to instead produce an allogenic version available to all.

logoSo, what is CAR-T? You can read a more in-depth explanation in our ‘Oncology therapies in Biotech’ review here, but in brief – Chimeric Antigen Receptors (CAR) therapies can be engineered to be expressed on specialised T-cells, which can then bind to and attack tumor cells with great specificity.

Cellectis had been investigating how to produce Universal CAR-T (UCARTs) antibodies en masse under ‘Good Manufacturing Practice‘ conditions in Industry. Now, their allogenic UCART candidates for blood cancers have been demonstrated to a pre-clinical level, the next step being human trials.

Their focal candidate in question is UCART19, a particular T-cell receptor which has been engineered using their proprietary TALEN gene-editing platform to target Acute Lymphoblastic leukemia (ALL) and Chronic Lymphocytic leukemia (CLL).

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member